What's new?
22/05/2017

Paris, France – 22 mai 2017 — Sofinnova Partners, un leader du capital-risque en Europe spécialisé dans les sciences de la vie, annonce la promotion de Graziano Seghezzi en tant que Managing Partners. Il rejoint le Managing Partnership composé de Antoine Papiernik, Denis Lucquin, et Monique Saulnier. Cette nomination donne un coup d’accélérateur à la dimension internationale de Sofinnova Partners.

C’est en 2001 que Graziano a démarré sa carrière dans le capital-risque chez Sofinnova Partners où il est chargé de trouver et analyser les nouvelles opportunités d’investissement. Tout au long de son parcours, il s’est engagé pour promouvoir la création d’entreprises, à la fois par des créations de start up, mais aussi par la réalisation de spin-offs et la mise en place d’accélérateurs. Il a été l’investisseur de démarrage d’Omthera Pharmaceuticals, initialement cotée sur le Nasdaq puis vendu à Astra Zeneca, de Glycovaxyn, vendu à GSK, et de Creabilis vendu à Sienna Biopharmaceuticals. Il a également investi et siège au conseil d’administration de Breath Therapeutics, Corvidia Therapeutics, Crescendo Biologics, Hookipa Biotech, Inotrem et Mission Therapeutics. Il a co-fondé BioVelocita, le premier accélérateur italien. Entre 2003 et 2006, Graziano travaille chez Index Ventures à Genève.

Scientifique de formation, il a passé cinq ans comme chercheur médical, spécialisé dans l’oncologie et les maladies cardiovasculaires, à l’Ecole de Médecine de NYU (Etats Unis). Graziano est diplômé de l’Université de Pavia (Italie) en génétique et microbiologie et détient un MBA de RSM Erasmus University.

Graziano Seghezzi déclare : « J’ai un respect immense pour l’équipe de Sofinnova, tant sur le plan professionnel que personnel ; et suis particulièrement fier d’avoir été promu Managing Partner. Ce nouveau rôle intervient à un moment charnière pour le Managing Partnership qui vient de définir un ambitieux projet de croissance. Avec mon expertise internationale, je suis heureux de participer à la consolidation du leadership global de Sofinnova Partners dans les sciences de la vies ».

Antoine Papiernik, Président de Sofinnova Partners, poursuit : « Graziano a démarré chez Sofinnova Partners il y a quinze ans alors qu’il entamait sa reconversion professionnelle de chercheur à investisseur dans les biotech. Aujourd’hui, Graziano a bâti un track record exceptionnel à la fois en Europe et aux Etats Unis, et nous sommes ravis qu’il rejoigne ainsi le Managing Partnership ».

 

Contact presse pour SOFINNOVA PARTNERS

Anne REIN

Tel:     +33 6 03 35 92 05

@:      anne.rein@strategiesimage.com

 

04/04/2017

Cambridge, UK, 4 April 2017 – Crescendo Biologics Ltd (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces that Dr Philip Bland-Ward has been appointed Chief Scientific Officer (CSO). The appointment will take effect in May 2017.
With over 20 years’ experience in the biopharmaceuticals industry, Phil has played a key role in the development of novel antibody therapeutics in multiple disease areas. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme. Phil previously held senior positions at Cambridge Antibody Technology and PanGenetics, and was CSO at Navion, as well as a co-founder of Nascient.
His in-depth experience with late stage, pre-clinical development programmes, including novel antibody drug candidates, complements Crescendo’s current in-house expertise and strengthens the Company’s positioning as a provider of novel immuno-oncology products with enhanced therapeutic potential.
Phil’s role as CSO will be to drive Crescendo’s immuno-oncology (IO) and Humabody® Drug Conjugate (HDC) programmes to clinical proof-of-concept.
Dr Peter Pack, CEO of Crescendo Biologics, said:
“Over the past 24 months, Crescendo has transitioned from a technology platform company to a developer of Humabody® therapeutics. We have created a rich internal pipeline of truly differentiated, multi-functional biologics with a focus on oncology. Our growing reputation is also leading to external collaborations and licensing deals with big pharma, such the recent deal signed with Takeda.
“Our aim now is to advance our programmes rapidly to the next stage of clinical development. Phil’s appointment as CSO, coupled with his experience and standing in the field of biologics development, will be key to achieving this.”
Dr Philip Bland-Ward, the new CSO, added:
“The IO field has been a key focus for biotech companies in the last few years and it’s an area where Crescendo’s Humabody® platform is ideally positioned. The Company has produced a pipeline of multi-functional biological candidates with exciting new modes-of-action and huge therapeutic potential. I look forward to working with the team at Crescendo to advance the development of Humabody® therapeutics in oncology.”

Background on Dr Philip Bland-Ward
Phil began his career working on pain and migraine research at the Glaxo Institute of Applied Pharmacology and then at GlaxoWellcome. He joined Cambridge Antibody Technology (CAT) to lead antibody projects in neuroscience, metabolic diseases, and ophthalmology. He was Director of Oncology Biology at CAT before moving to PanGenetics to successfully lead the development of their antibody assets (pain, auto-immune disease), underpinning progression to Phase I clinical studies.
Subsequently Phil took roles as CSO of Navion (oncology) and SweetSpot Therapeutics, and co-founded Nascient (inflammatory disease) – all small companies focused on discovery and development of antibody therapeutics.
Prior to joining Crescendo, Phil was a VP at Kymab with particular responsibility for the scientific leadership of their most advanced development programme.
Phil holds a BPharm degree in pharmacy and a PhD in pharmacology, both from King’s College London.

For more information, please contact: Crescendo Biologics Dr Peter Pack, CEO Tel: 44 (0)1223 497140 info@crescendobiologics.com Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell Tel: 44 (0)20 7457 2020 crescendo@instinctif.com ICR Inc. Stephanie Carrington/James Heins Tel: 646-277-1282/203-682-8251 crescendo@icrinc.com

Notes to Editors:
About Crescendo Biologics Ltd
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated mono- and multi-functional Humabody® therapeutics in oncology. The Company’s Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH) with superior biophysical properties and developability.
Crescendo is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs.
Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.
For more information, please visit the website: www.crescendobiologics.com .

About Humabody® Therapeutics
Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human VH domain building blocks (Humabody® VH) isolated from heavy chain-only antibodies produced using Crescendo’s proprietary transgenic mouse.
Compared with monoclonal antibodies, Humabodies offer a unique combination of potential benefits resulting from their small size, cost-effective production and robust biophysical properties. These attributes allow Crescendo to optimally configure an almost limitless range of multifunctional Humabody® formats in a rapid timeframe.
Crescendo is developing a pipeline of novel, Humabody®-based therapeutics in oncology. Its next-generation mono- and multi-specific Humabody® immune-oncology modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response, as well as enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Its Humabody® Drug Conjugates (HDCs) deliver a superior therapeutic index to standard ADCs.
For more information, please visit the website: www.crescendobiologics.com.

28/03/2017

• Il succède à Denis Lucquin, Président de Sofinnova Partners pendant dix ans, qui demeure l’un des Managing Partner de la société de capital-risque.
• Sofinnova Partners donne un nouvel élan à sa stratégie de croissance pour conforter sa position de leader en Europe de l’investissement dans les sciences de la vie.

Paris, France – 28 mars 2017 — Sofinnova Partners, un leader du capital-risque en Europe spécialisé dans les sciences de la vie, annonce la nomination d’Antoine Papiernik en tant que Président. Il succède à Denis Lucquin qui demeure Managing Partner. Cette nomination marque une nouvelle impulsion dans la stratégie de croissance de Sofinnova Partners.

Antoine Papiernik a rejoint Sofinnova Partners en 1997 et se distingue par un track record remarquable, investissant au démarrage de nombreuses sociétés qui ont été cotées sur les places boursières internationales ou rachetées par les acteurs les plus influents du secteur. Antoine a été le premier investisseur dans des sociétés cotées comme Actelion, ProQR, NovusPharma, Movetis, Mainstay, Pixium Vision ou Stentys côtées à la bourse de Zürich, au NASDAQ, sur le Nouveau Marché à Milan, sur Euronext Bruxelles, à la bourse de Dublin et sur Euronext Paris. Il a aussi investi à leur fondation dans CoreValve (vendue à Medtronic), Fovea (vendue à Sanofi) et Ethical Oncology Science (vendue à Clovis Oncology). Il est investisseur et siège aux conseils d’administration de Gecko Biomedical, MD Start, Shockwave Medical, Rgenix, Corwave, et Reflexion Medical. Antoine est titulaire d’un MBA de la Wharton School, Université de Pennsylvanie. En 2011 et 2012, il a été choisi par le magazine Forbes pour figurer dans la Midas List des 100 capital-risqueurs les plus influents.

Denis Lucquin déclare : « La transmission de flambeau est un acte majeur pour un partnership et nécessairement fondé sur une confiance absolue. Sofinnova Partners s’engage dans une nouvelle période, et c’est le moment idéal pour une telle transition. Antoine s’est imposé par la qualité de ses investissements et est devenu une figure incontournable du capital-risque, tant en Europe qu’aux Etats Unis. Il est aussi un meneur d’équipe talentueux. Il est la personne idéale pour répondre aux nouveaux défis et piloter les développements à venir ».

Antoine Papiernik poursuit : « C’est un honneur de succéder à Denis. Au cours des dix dernières années, sous sa présidence, nous avons mené avec succès le recentrage de nos activités sur notre cœur de métier, les sciences de la vie. Grâce à la confiance de nos investisseurs, nous avons considérablement accru le montant des actifs sous gestion, qui atteignent aujourd’hui 1,6 milliard d’euros. Dans la période qui s’ouvre, nous devrons concrétiser notre vision consistant à faire grandir Sofinnova Partners et à consolider notre position comme l’un des premiers acteurs de l’investissement dans les sciences de la vie ».

Les développements récents de Sofinnova Partners sont marqués par des succès multiples : la réalisation de sorties pour une valeur d’entreprise totale de plus de 4 milliards d’euros sur les quatre dernières années, grâce à 10 introductions en bourse sur cette période, et plusieurs cessions industrielles comme celle de Delinia, rachetée par Celgene en janvier 2017 pour une valeur totale de 775 M$ (725 M€).

Dans les années à venir, Sofinnova Partners entend accélérer son expansion dans les sciences de la vie en s’appuyant sur des équipes et des véhicules d’investissement dédiés. Après la clôture en décembre 2015 du fonds Capital VIII (300M€) consacré aux investissements « early stage » dans la santé, Sofinnova vient d’annoncer le premier closing à hauteur de 106 M€ du fonds IB 1 dédié à la biotech industrielle. D’autres véhicules d’investissements sont à l’étude autour de la thématique de la santé. Très internationale, l’équipe actuelle compte 29 personnes, représentant 10 nationalités. Au gré du déploiement de sa stratégie, la société prévoit d’étoffer ses équipes avec un nombre important de recrutements au cours des deux prochaines années.

27/03/2017

LEIDEN, the Netherlands, March 27, 2017 – ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational medicine, rare disease drug development, and RNA therapeutics. Dr. Rodman’s experience includes a leadership role in developing two approved medicines for cystic fibrosis (CF) at Vertex Pharmaceuticals, as vice president and head of respiratory drug development. He was also the head of translational medicine at Novartis Institute for Biomedical Research. More recently, he was the Chief Medical Officer at MiRagen and Nivalis. Expansion of the ProQR management team will allow the company to unlock the potential of RNA therapeutics as well as expand business capabilities needed to advance the development of our product candidates that now include three programs: QR-010 for CF, QR-110 for Leber’s congenital amaurosis Type 10, and QR-313 for dystrophic epidermolysis bullosa.

“At ProQR we are just beginning to capitalize on the power of RNA based therapeutics. We believe RNA therapeutics offers a powerful therapeutic approach to severe genetic disease. We believe the RNA approach has advantages over other approaches, and we are excited to fully explore the possibilities for patients. By adding Dave to our leadership, we will be able to strengthen our portfolio and strategically build our pipeline of RNA approaches to treating disease.” said Noreen R. Henig, MD, Chief Medical Officer.

“There are very few opportunities like ProQR where a great team, cutting edge science and the passion for patients come together” said David M. Rodman, MD, “In joining ProQR I look forward to continue to make an effort for CF patients, but also on making a big impact for patients suffering from other rare diseases.”

“In the ProQR tradition of only working with the best of the best, I’m very pleased that Dave is joining our team” said Daniel de Boer, Chief Executive Officer of ProQR. “Between Gerard (Platenburg, Chief Innovation Officer), Dave and Noreen we cover all key capabilities from invention to translation to late stage development.”

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

About Cystic Fibrosis
CF is the most common fatal inherited disease in the Western world and affects an estimated 65,000 patients worldwide. In people with CF, a defective CFTR gene causes a thick, buildup of mucus in the lungs, pancreas and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure. There is no cure for CF. Disease manifestations lead to a shortened life expectancy with a median age of death of 30 years or less. Although over 1,900 CF-causing gene mutations have been identified, approximately 85% of all CF patients are affected by the F508del mutation. Among all CF patients, approximately 45% are homozygous for the F508del mutation.

About Leber’s Congenital Amaurosis Type 10
Leber’s congenital amaurosis is the most common genetic cause of blindness in children and consists of a group of diseases of which LCA Type 10 (LCA 10) is one of the more severe forms. LCA 10 leads to progressive loss of vision causing most patients to lose their sight in the first few years of life. To date, there are no treatments approved or product candidates in clinical development that treat the underlying cause of this specific subtype of the disease. LCA 10 is caused by mutations in the CEP290 gene of which the p.Cys998X mutation is most common. Although prevalence rates vary, we believe approximately 2,000 people in the Western world have LCA 10 because of this mutation.

About Dystrophic Epidermolysis Bullosa
Dystrophic epidermolysis bullosa (DEB) is a rare genetic disorder of the skin and mucosal membranes and is characterized by fragile skin, severe blistering and poorly healing wounds that result from minimal pressure. Some forms of DEB are painful and debilitating and are associated with very low quality of life and a limited life expectancy. The disease is caused by mutations in the COL7A1 gene that lead to a weak connection between the dermis (inner layer) and the epidermis (outer layer) in the skin. Approximately 2,000 patients have DEB because of mutations in exon 73 of the COL7A1 gene. There is currently no treatment available.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-010, QR-110 and QR-313, statements regarding our ongoing and planned discovery and development of existing and future product candidates, statements regarding our RNA approach to treating diseases and statements regarding the appointment of David M. Rodman to our management team. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
ir@proqr.com

14/03/2017
  • L’opération a été plusieurs fois sursouscrite, notamment par les investisseurs institutionnels internationaux.
  • La capitalisation boursière d’Avantium atteint 277 M€ après une augmentation de capital de 103 M€.
  • L’introduction en bourse d’Avantium valide clairement les choix stratégiques de Sofinnova Partners dans les biotech industrielles et la chimie du renouvelable.

Paris, France – 14 mars 2017. Sofinnova Partners, société de capital-risque dans les sciences de la vie basée à Paris, annonce le succès de l’introduction en bourse d’Avantium qui a levé 103 M€ sur Euronext Amsterdam et Euronext Bruxelles. Sofinnova Capital VI reste le principal actionnaire de la société. L’opération en bourse a été plusieurs fois sursouscrite.

Basée à Amsterdam, Avantium est une entreprise pionnière de la chimie renouvelable qui à partir de matériaux d’origine biologique développe des processus efficaces et des produits durables. Parmi ses nombreuses réussites, on trouve notamment la technologie YXY qui permet de produire du PEF : un plastique entièrement nouveau et de grande qualité, créé à partir de sucres industriels. Le PEF est 100 % recyclable et offre une solution rentable pour une utilisation allant des bouteilles aux films et fibres d’emballage, le positionnant pour devenir le matériel de conditionnement de la prochaine génération.

Les fonds levés permettront d’accélérer la commercialisation de ses produits, et en particulier de lancer la commercialisation de sa technologie YXY, en coentreprise avec BASF, grâce à la construction de la première installation à échelle commerciale pour le FDCA. C’est une étape importante dans le développement stratégique d’Avantium, dont l’objectif est de devenir un leader mondial dans la chimie renouvelable. Avantium se distingue pour sa faculté à attirer des partenaires réputés à l’échelle mondiale, tout au long de la chaîne de valeur, tels que The Coca-Cola Company, Danone, Toyobo, ALPLA et Mitsui. Parallèlement à la technologie YXY, la société travaille sur une série d’autres projets, qui pour certains ont déjà atteint ou entrent dans la phase pilote.

Denis Lucquin, Managing Partner de Sofinnova Partners et membre du Conseil d’administration d’Avantium depuis 2011, déclare : « Avantium a réalisé une des plus belles introductions en bourse dans le secteur émergent et plein d’avenir qu’est la chimie du renouvelable. Elle valide à elle seule la vision et stratégie de Sofinnova Partners, qui vient d’annoncer la première clôture d’un fonds, Sofinnova IB I, entièrement consacré à cette industrie émergente. En tant qu’investisseur historique et toujours premier actionnaire de la société après cette opération, nous sommes extrêmement heureux du succès de cette opération. Il atteste de la confiance des investisseurs dans le talent de l’équipe d’Avantium et sa capacité à transformer un projet visionnaire en une entreprise performante à dimension mondiale ».

Au total, le nombre d’actions émises s’établit à 9 401 793, permettant la réalisation d’une augmentation de capital de 103 M€.  Sur la base d’un prix par action de 11 €, la capitalisation boursière d’Avantium s’élève à 277 M€ à l’issue de l’opération. Les actions seront négociées sur Euronext Amsterdam et Euronext Bruxelles sous le symbole AVTX à compter du 15 mars 2015. Se référer au communiqué de la société (www.avantium.com) pour de amples informations sur l’opération.

 

A propos de Sofinnova Partners
Sofinnova Partners est un des leaders du capital risque en Europe spécialisé dans les sciences de la vie. Basée à Paris, l’équipe est composée de 12 professionnels de l’investissement issus d’Europe, des Etats Unis et de Chine. La société investit dans les technologies de changement de paradigme aux côtés d’entrepreneurs visionnaires. Sofinnova Partners intervient en priorité dans les start up et spin-off d’entreprises en tant qu’investisseur fondateur et chef de file. Depuis plus de 40 ans, la société a accompagné plus de 500 entreprises à travers le monde devenues des leaders sur leur marché. Sofinnova Partners gère aujourd’hui 1,5 milliard d’euros.  Pour plus d’information : www.sofinnova.fr

À propos d’Avantium
Avantium est une entreprise de technologie chimique de premier plan et un précurseur dans la chimie renouvelable. Avec ses partenaires aux quatre coins du monde, Avantium développe des processus efficaces et des produits durables à partir de matériaux d’origine biologique. Avantium offre un terrain d’expérimentation pour des solutions révolutionnaires de chimie renouvelable.  De l’invention jusqu’aux processus de production commercialement viables. Parmi les nombreuses réussites d’Avantium, on trouve notamment la technologie YXY qui permet de produire du PEF : un plastique entièrement nouveau et de grande qualité, créé à partir de sucres industriels. Le PEF est 100 % recyclable. Il offre une solution rentable pour une utilisation allant des bouteilles aux films et fibres d’emballage, le positionnant pour devenir le matériel de conditionnement de la prochaine génération. Pour plus d’information : www.avantium.com

08/03/2017

– Led by top-tier life science venture capitalists Gimv and Sofinnova Partners
– Funds to execute pivotal program in Bronchiolitis Obliterans Syndrome

Munich, Antwerp, Paris, Utrecht, March 8th, 2017 — Breath Therapeutics Holding BV (Breath Therapeutics), a company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, today announced the closing of a EUR 43.5 million Series A financing. Gimv and Sofinnova Partners co-led the round and were joined by Gilde Healthcare. PARI Pharma supports the program. With the proceeds from the financing, Breath Therapeutics plans to conduct phase 3 trials in Europe and the US, respectively, submit for marketing approval, and prepare for commercialization.
Breath Therapeutics’ lead program develops a first-in-class inhalation therapy for treatment of Bronchiolitis Obliterans Syndrome (BOS). BOS is a lethal orphan respiratory disease, mainly affecting lung transplant patients. It is commonly understood as chronic graft rejection and is the main reason for the poor 5-year survival rates after lung transplantation.
Based on work by PARI Pharma and lung transplantation expert Aldo Iacono, MD, University of Maryland, USA, Breath Therapeutics develops a proprietary drug/device combination. This involves a formulation of liposomal cyclosporine A for inhalation and an optimized high performance eFlow® technology nebulizer enabling remote adherence monitoring. This approach is expected to ensure a safe, well tolerated and targeted delivery of immunosuppressive medication directly into the lungs along with a time saving treatment regime.
Breath Therapeutics is a spin-off of PARI Pharma, Starnberg, Germany. The company’s founding and management team includes highly experienced executives and internationally renowned experts in drug aerosol and immunosuppression therapy: Dr. Jens Stegemann (CEO), Anne Burger (CFO), Dr. Gerhard Boerner (CSO) and Dr. Oliver Denk (COO). Graziano Seghezzi, partner at Sofinnova Partners, Dr. Karl Nägler, partner at Gimv, and Arthur Franken, partner at Gilde Healthcare, will join the board of directors.
Dr. Jens Stegemann, CEO of Breath Therapeutics, said: “BOS is one of the most devastating lung diseases and still today, no effective therapy is available. Our strategy is to deposit high concentrations of an immunosuppressive agent directly into the small airways of the lung. With this top-tier group of investors and the best international lung transplantation centres supporting us, we now are in an excellent position to achieve ground-breaking improvements in the combat of BOS.”
Graziano Seghezzi, partner at Sofinnova Partners, added: “We are thrilled to be involved with Breath Therapeutics. We were really impressed by its highly talented and entrepreneur-oriented team, as well as by the potential of its market breaking technology. At Sofinnova Partners we have a strong expertise in turning corporate spin-offs into successful companies, and are happy to share our experience and resources with the team to back Breath Therapeutics’ growth.”
Dr. Karl Nägler, partner at Gimv, commented: “It is a great opportunity to invest in a company focusing on a life-threatening orphan disease with high unmet medical need. We were attracted by the strong expertise of the founding team and by the very promising late-stage clinical data. Furthermore, the BOS market will allow for a focused and highly profitable commercialisation strategy.”
Arthur Franken, partner at Gilde Healthcare, said: « This talented team has designed a unique drug/device combination which together with digital adherence monitoring has great potential to improve quality of care for patients suffering from chronic lung graft rejection. Gilde will actively support Breath Therapeutics and its team in its growth strategy of developing and commercializing inhaled drug therapies for severe respiratory disease. »
Dr. Martin Knoch, President of PARI Pharma, said: “The team at Breath Therapeutics has the expertise and focus to bring the first lung-targeted BOS therapy through clinical development and hopefully onto the market. For PARI Pharma it is highly rewarding to see a project that we started advancing into late-stage clinical development and providing BOS patients new hope.”

About Breath Therapeutics
Breath Therapeutics is specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases. For its clinical development, the company is using proprietary drug formulations optimized for inhaled administration with exclusively licenced, high performance nebulizers. Breath Therapeutics is focussing on integrated therapy solutions in the interaction between diagnostic, therapy and eHealth therapy control. The clinical development program is addressing the treatment of Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. PARI Pharma, a leading nebulizer company, is strategic partner and technology licensee for the BOS development program. Breath Therapeutics is based in Munich and Frankfurt, Germany.
For more information, please visit: www.breath-therapeutics.com.

About Gimv
Gimv is a European investment company with over three decades’ experience in private equity and venture capital. The company is listed on Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including co-investment partnerships) of investments in about 50 portfolio companies. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.
For more information, please visit: www.gimv.com.
About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over € 1.6 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.
For more information, please visit: www.sofinnova.fr.

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a European specialist investment firm focused on private healthcare companies. It has over € 800 million ($ 900 million) under management and is actively looking to lead new investments in therapeutics, medical devices, digital health and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to € 30 million in a single portfolio company. Gilde is currently investing out of GHC IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility.
For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

About PARI Pharma GmbH
PARI Pharma recognizes that the future of aerosol therapies is the combined optimization of the drug formulation and the delivery device – a core competence of PARI Pharma in the global network of PARI Worldwide companies. The focus of PARI Pharma is the optimization of advanced aerosol delivery platforms, based on the eFlow Technology, with new liquid medications. The goal is to enable short and effective treatments that lead to increased patient adherence, disease control, and improved quality of life for patients. By optimizing drug and device under one roof, PARI Pharma increases the speed of development for pharmaceutical partners.
For more information, please visit www.paripharma.com.

Contact:
MC Services AG
Raimund Gabriel, Managing Partner.
Tel. +49 89 210 228–60
Email: breath-therapeutics@mc-services.eu

07/03/2017

Ghent, Belgium, March 7, 2017 – AgroSavfe NV, a Belgium-based agro-biotech company, announced today that it extended its Series B financing round to €11 million.
The funds will be used to accelerate the development of the Company’s novel Agrobodies® as a new generation of biopesticides and to roll out the international registration process. Agrobodies® are small proteins that are designed and formulated to specifically bind to essential target molecules of crop pests and diseases. AgroSavfe has generated Agrobodies® with antifungal activity and is developing these into a novel class of biofungicides. The company is pursuing an ambitious global product development program from its R&D centre at the Technologiepark in Ghent.
Sofinnova Partners joins earlier investors Agri Investment Fund, Biovest, Gimv, Globachem, Madeli Participaties, PMV, Qbic and VIB.
“We are very impressed with the potential of the Agrobody technology. Agro chemicals, and in particular fungicides and insecticides, are huge markets that biologicals can address if they can be scaled up and produced at competitive cost compared to chemical compounds. This is central to our investment philosophy for Sofinnova IB I, our new fund in industrial biotech, that is dedicated to renewable chemistry.” said Denis Lucquin, Managing Partner of Sofinnova Partners. Lieven De Smedt, chairman of the board of AgroSavfe adds: “Started in 2013 as a spin off from VIB, AgroSavfe has now become a truly international AgTech company with a proven technology platform, an experienced team and a Board with top-league seasoned investors and entrepreneurs. Needless to say that it is a great pleasure that Denis joins our new Board to help AgroSavfe to become a world player in biopesticides, serving both conventional and biological farming.”
About AgroSavfe NV
AgroSavfe NV, a Belgian Agro-Biotech company, established as a spin-off from VIB, develops camelid binding domains, or Agrobodies®, for diverse applications in agriculture. AgroSavfe has demonstrated that its Agrobodies® provide control of a broad range of plant pathogenic fungi and is developing a new generation of biopesticides.

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.6 billion under management.For more information, please visit: www.sofinnova.fr

Contact
AgroSavfe NV
Lieven De Smedt, Chairman of the Board
lieven.de.smedt@agrosavfe.com
+32 (474) 073 193

07/03/2017

Vienna, Austria, 6 March 2017 – Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from today.

Dr. Matushansky joins Hookipa from Daiichi Sankyo, where he was the Global Head of Translational Development for Oncology. He led Daiichi Sankyo’s international research unit focused on early oncology therapeutic programs, strategy and development, and was accountable for development activities from post-target identification basic science research to first-in-man trials and proof-of-clinical concept. Prior to that, Dr. Matushansky was at Novartis where he was Global Head for Clinical and Scientific Development at its Gene & Cell Therapy Unit as well as a Global Clinical Program Lead within Novartis’ Oncology Translational Medicine Unit.
Before being recruited to the pharmaceutical industry, Dr. Matushansky was a Professor at the Columbia University Medical Center where he ran an independent laboratory and clinic focusing on the molecular biology, translational opportunities and clinical trials in sarcomas. Currently he is an Adjunct Professor of Medical Oncology, Columbia University. He grew up in New York City where he received his undergraduate B.A. degree, summa cum laude, from Columbia University. He then went on to attend the Albert Einstein College of Medicine where he received his MD as well as a PhD in Molecular Biology. He performed his Internal Medicine residency at New York Presbyterian Hospital – Weill Cornell Medical Center and then completed a fellowship in Medical Oncology as well as a post-doctoral research fellowship in Cancer Biology at the Memorial Sloan Kettering Cancer Center.
Commenting on the appointment, Hookipa’s CEO, Mr. Joern Aldag said: “Dr. Matushansky’s valuable experience heading up R&D units at big pharma coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our Company from prophylactic to therapeutic immuno-oncology focused therapies. His impressive and extensive professional background makes him a perfect fit for our leadership team during an important time in our Company’s growth. I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”

Dr. Matushansky said, “TheraT® has real potential both alone and in combination with other immune-modulators and/or targeted therapies to improve not only the current clinical outcomes but the quality of life for a wide array of cancer patients. It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”
About Hookipa Biotech
Hookipa Biotech is developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. To date, Hookipa has raised EUR 13.7 million in non-dilutive funds and EUR 37 million equity investment from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners. Additional information on Hookipa is available at www.hookipabiotech.com.

About Vaxwave®
Hookipa’s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. In this vector the gene encoding the viral envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with a target gene “of interest.” The resulting vectors infect target cells and stimulate very potent and long-lasting immune responses, however they can no longer replicate and are therefore non-pathogenic and inherently safe. HB-101, a cytomegalovirus (CMV) prophylactic vaccine, is in a clinical phase 1 trial and has already shown to be both safe in humans and to elicit potent antibody and T cell responses. We are confident to establish HB-101 as the best-in class CMV development program.
About TheraT®
Hookipa’s TheraT® platform is based on an attenuated replicating virus and is capable of eliciting the most potent T cell responses – a crucial step in treating patients with aggressive cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable of eliciting > 50% antigen-specific T cell responses and strong tumor control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced head and neck cancer is currently being prepared. This immuno-oncology technology is further being leveraged to target tumor self-antigens or shared neoantigens.

Issued for and on behalf Hookipa Biotech AG by Instinctif Partners.
For further information please contact:

At the Company
Joern Aldag
Chief Executive Officer
Hookipa Biotech AG
Office@Hookipabiotech.com

Marine Popoff
Communications Analyst
Hookipa Biotech AG
Mpopoff@Hookipabiotech.com

Media enquiries
Sue Charles/ Daniel Gooch/ Alex Bannister
Instinctif Partners
hookipa@instinctif.com
+44 (0)20 7866 7905

02/03/2017

Paris, France – 2 mars 2017 — Sofinnova Partners, un leader du capital risque en Europe spécialisé dans les sciences de la vie, annonce avoir levé 106 millions d’euros lors de la première clôture de son fonds Sofinnova Industrial Biotech 1 (Sofinnova IB I). Ce fonds, dédié à la chimie du renouvelable, est dans la continuité des 9 investissements réalisés dans ce domaine depuis 2009, et positionne Sofinnova Partners à la pointe de ce secteur d’avenir en plein essor.

Sofinnova IB I ciblera les start-up opérant sur l’ensemble de la chaîne de valeur. Il investira aussi bien dans la transformation des matières premières renouvelables comme les déchets agricoles ou le C02, que dans la mise au point de produits transformés tels que les bio-plastiques et autres matériaux bio-sourcés. Une attention particulière sera accordée aux projets industriels issus des progrès récents de la biologie, comme la biologie de synthèse. Cette stratégie d’investissement répond à la demande croissante du marché pour des produits innovants et renouvelables, offrant des alternatives plus performantes et/ou moins chères aux produits d’origine fossile.

Dans la continuité de ses fonds précédents, Sofinnova Partners investira en tant qu’investisseur chef de file dans les start-up et spin-off d’entreprises, en Europe et en Amérique du Nord. Le fonds accompagnera, du laboratoire au marché, des entrepreneurs visionnaires développant des innovations de rupture. Sofinnova IB I prévoit d’investir dans 8 à 10 entreprises au cours des 3 à 4 prochaines années. Pour ce faire, il s’appuiera sur une équipe dédiée expérimentée, composée initialement de Denis Lucquin, Managing Partner, Joško Bobanovic, Partner, et Michael Krel, Principal.

Pour cette première clôture, Sofinnova IB I a su attirer un pool d’investisseurs de premier plan, principalement des institutionnels européens et des acteurs industriels internationaux issus du monde de l’énergie, de la chimie et de l’agriculture, parmi lesquels plusieurs investisseurs ayant participé au fonds d’amorçage levé en 2012 dans le même domaine : Sofinnova Green Seed Fund.

Denis Lucquin, Managing Partner de Sofinnova Partners, déclare, “Nous sommes ravis du succès de ce premier closing. L’expérience acquise depuis 2009 a été extrêmement bien accueillie par les investisseurs. Avec des sociétés comme Avantium, qui développe des bouteilles en plastique entièrement bio-sourcées et prévoit une introduction en bourse sur Euronext, ou plus récemment DNA Script qui révolutionne la synthèse de l’ADN, Sofinnova Partners s’affirme comme un investisseur pionnier, avec une compréhension fine des dynamiques de ce secteur en plein essor. Grâce à ce fonds dédié, notre activité dans les biotech industrielles vient de franchir un cap décisif.”

* The Fund is supported by InnovFin Equity plus de détails

A propos de Sofinnova Partners
Sofinnova Partners est un des leaders du capital risque en Europe spécialisé dans les sciences de la vie. Basée à Paris, l’équipe est composée de 12 professionnels de l’investissement issus d’Europe, des Etats Unis et de Chine. La société investit dans les technologies de changement de paradigme aux côtés d’entrepreneurs visionnaires. Sofinnova Partners intervient en priorité dans les start up et spin-off d’entreprises en tant qu’investisseur fondateur et chef de file. Depuis plus de 40 ans, la société a accompagné plus de 500 entreprises à travers le monde devenues des leaders sur leur marché. Sofinnova Partners gère aujourd’hui 1,5 milliard d’euros.
Pour plus d’information : www.sofinnova.fr

Press contact for SOFINNOVA PARTNERS
Anne REIN Tel: +33 (0)6 03 35 92 05 @: anne.rein@strategiesimage.com

28/02/2017

Investment from new and current investors will be used to advance Comet’s second-generation dextrose plant in Sarnia, Ontario
Agricultural residues to be converted into high-purity dextrose for production of sustainable bio-chemicals

London, Ontario – 28 February 2017 – Comet, an industry leader in the production of high-purity cellulosic dextrose, today announced the completion of a round of equity financing led by new investor PM Equity Partner. Current investor Sofinnova Partners and new investor Bioindustrial Innovation Canada (BIC) also participated in the financing. Terms of the financing were not disclosed.

Comet’s industrial technology converts agricultural residues into high-purity dextrose for production of sustainable bio-chemicals. Comet’s cellulosic sugar is not only cost- and quality-competitive with corn or sugarcane derived products, but importantly, it does not hamper food production and has a superior carbon footprint, improving the sustainability profile of the produced biochemical. The investment will be used to advance the commercialization of Comet’s secondgeneration sugar production platform and fund construction of the company’s previously announced 60 million pounds per year dextrose facility in Sarnia, Ontario.

“We are very pleased to announce this new round of financing, with strong support from Sofinnova Partners and our new investors. The investment reflects confidence in our low-cost, high-purity cellulosic dextrose technology and enables us to deliver on a key missing piece in the value chain – a viable source of renewable sugars from non-food biomass,” said Rich Troyer, CEO of Comet.

Joško Bobanović of Sofinnova Partners commented, “We look forward to supporting the Comet management team as they take the company and the technology to the next level. Comet’s project is now well-positioned to enable profitable production of truly commercial quantities of second-generation sugars and co-products for bio-based applications.”

In March 2016, with strong support of BIC, Comet Biorefining partnered with the Cellulosic Sugar Producers Cooperative located in Western Ontario. The Ontario farmer group plans to invest in and supply corn stover and wheat straw feedstock to Comet’s commercial plant. Sandy Marshall, Executive Director of BIC noted that “The recent investment allows us to continue to support Comet Biorefining’s mission to integrate regional supply chains with innovative new technology partners and enable Sarnia-Lambton to become a leader in the development of sustainable, bio-based products.”

About Comet Biorefining
Comet Biorefining is a leading provider of sustainable, high-quality, costcompetitive cellulosic dextrose technology for applications in renewable biochemicals and biofuels. Comet Biorefining operates a demonstration scale plant in Rotondella, Italy, owned by ENEA – the Italian National Agency for New Technologies, Energy and Sustainable Economic Development. In February 2016, Comet Biorefining announced the construction of a 60 million pounds per year commercial sugar plant to come online in 2018. The company plans to build, own and operate its own plants and will strategically license its technology to select partners on a worldwide basis to meet the growing demand for bio-based products. For more information, visit www.cometbiorefining.com.

About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France.
For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit. For more information, please visit: www.sofinnova.fr

About PM Equity Partner
PM Equity Partner is the corporate venture and private equity investment arm of Philip Morris International. For more information, visit
www.pmequitypartner.com

About Bioindustrial Innovation Canada (BIC)
Bioindustrial Innovation Canada (BIC) is a Canadian not-for-profit organization catalyzing the commercialization of Cleantech with a focus on bio-based and sustainable chemistry-based technologies including advanced biofuels, biochemicals, biomaterials and bio-ingredients. Based in Sarnia, Ontario, the BIC mission is to create jobs and economic value sustainably in Canada. For more information, visit www.bincanada.ca

Media Contact
Janaina Topley Lira
Sustainability Consult
jtl@sustainabilityconsult.com
+32 2 347 1101

22/02/2017

PARIS, France et CAMBRIDGE Mass. USA – 21 février 2017 – Lysogene, (la « Société » FR0013233475 – LYS) société biopharmaceutique spécialisée dans la thérapie génique ciblant les maladies du système nerveux central (SNC), annonce aujourd’hui que l’Agence Européenne des Médicaments (EMA) a accordé la désignation de médicament orphelin au LYS-GM101, candidat médicament de la Société pour le traitement de la Gangliosidose à GM1 (GM1). La FDA (Food and Drug Administration) aux États-Unis a également accordé les désignations de médicament orphelin et de maladie rare pédiatrique au LYS-GM101 au début de l’année. « La désignation de médicament orphelin par l’EMA pour LYS-GM101 est une importante étape réglementaire. Elle valide la crédibilité de notre approche médicale et facilitera et accélérera le développement clinique de notre traitement. C’est une bonne nouvelle pour les patients atteints de cette maladie neurodégénérative grave et nous avons hâte de démarrer l’étude clinique de phase I/II (LYS-GM101) en 2018 », déclare Karen Aiach, Fondatrice et Directrice Générale de Lysogene. LYS-GM101 est conçu afin de corriger l’action d’un gène défectueux dans les cellules des patients atteints de GM1, ce qui permettra de produire une enzyme fonctionnelle et de prévenir la nature progressive des dommages neurologiques causés par GM1. À propos de la désignation de médicament orphelin
Une désignation de médicament orphelin par l’EMA permet à une entreprise pharmaceutique de bénéficier d’aides de l’UE pour développer un médicament contre une maladie rare. Les candidatures sont examinées par le Comité des Médicaments Orphelins (COMP), qui émet un avis, transmis à la Commission Européenne (CE). La CE décide ensuite si elle accorde la désignation de médicament orphelin pour le traitement en question, sous 30 jours après réception de l’avis du COMP. Les entreprises pharmaceutiques ayant obtenu la désignation de médicament orphelin bénéficient de plusieurs avantages, notamment un soutien au niveau du protocole, un type d’avis scientifique spécialisé dans les médicaments désignés orphelins, et une exclusivité de marché une fois que le médicament est autorisé. Des réductions sont également disponibles, en fonction du statut et du type de service requis.

À propos de GM1
La Gangliosidose à GM1 est une maladie rare neurodégénérative caractérisée par des retards cognitifs et moteurs de développement graves entraînant la mort précoce. La maladie est causée par une mutation du gène GLB1 qui code pour la bêta-galactosidase, une enzyme nécessaire au recyclage de la molécule GM1-gangliosidose dans les neurones. Ce lipide du cerveau est essentiel pour un fonctionnement normal, mais son accumulation entraine une neurodégénerescence et des symptômes neurologiques sévères. À la connaissance de la Société, il n’existe à ce jour aucun traitement permettant de stabiliser ou ralentir l’état clinique des patients atteints de GM1.

À propos de Lysogene
Lysogene est une société de biotechnologie au stade clinique, pionnière dans la recherche fondamentale et le développement clinique de thérapies géniques utilisant des vecteurs dérivés de virus adéno-associés pour traiter des maladies rares et mortelles du SNC de l’enfant, pour lesquelles il n’existe aujourd’hui, à la connaissance de la Société, aucun traitement. Depuis 2009, Lysogene a mis en place une solide plateforme et un réseau important, avec des produits innovants dans la MPS IIIA et dans la gangliosidose à GM1. Lysogene a obtenu la désignation de médicament orphelin par la FDA et l’EMA, et la désignation de maladie rare pédiatrique par la FDA, pour le programme MPS IIIA.
Lysogene est cotée sur le marché réglementé d’Euronext à Paris d’Euronext à Paris (code ISIN : FR0013233475)
Pour plus d’informations : www.lysogene.com.

Contacts Europe:
Relations Presse: NewCap
Annie Florence
afloyer@newcap.fr
+ 33 6 88 20 35 59
+ 33 1 44 71 00 12
Chris Maggos
Managing Director, Europe
LifeSci Advisors
chris@lifesciadvisors.com
+41 79 367 6254
Contacts USA:
Marion Janic
RooneyPartners
mjanic@rooneyco.com
+ 1 (212) 223-4017